Source:http://linkedlifedata.com/resource/pubmed/id/20849904
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2010-11-10
|
pubmed:abstractText |
Expression of leucine, leucine-37 (LL-37) is enhanced in keratinocytes of skin lesions with psoriasis. We examined serum LL-37 levels in patients with psoriasis vulgaris. Serum LL-37 levels in patients were higher than in normal controls, and were reduced after cyclosporine A treatment. In both groups, LL-37 and interleukin (IL)-17 levels inversely correlated. In patients, LL-37 levels correlated with interferon (IFN)-? and IL-10 levels. In controls, LL-37 levels inversely correlated with tumor necrosis factor (TNF)-?, IL-6, IL-1?, and IL-22 levels. IFN-?, IL-17, IL-22, TNF-?, IL-6, and IL-1? enhanced, and IL-10, IL-4, IL-13, and cyclosporine A suppressed, LL-37 secretion from keratinocytes and neutrophils. LL-37 enhanced IFN-?, IL-4, IL-13, and TNF-? secretion from CD3/CD28-stimulated T cells, suppressed TNF-?, IL-1?, IL-6, and IL-10 secretion from lipopolysaccharide-stimulated monocytes, and IL-17, IL-22, IL-1?, IL-6, and IL-10 secretion from CD3/CD28-stimulated T cells. LL-37 may sustain its production by enhancing IFN-? or reducing IL-10 production, while suppressing its production by reducing IL-17, IL-22, TNF-?, IL-1?, or IL-6 and enhancing IL-4 or IL-13 production. In patients, systemic LL-37 production is enhanced, and an IFN-?/LL-37-positive feedback loop may exist. In controls, negative feedback by LL-37 on TNF-?, IL-1?, IL-22, and IL-6 may exist. In both groups, negative feedback by LL-37 on IL-17 may exist. LL-37 may act as an effector and regulator.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1879-1166
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright © 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
71
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1161-71
|
pubmed:meshHeading |
pubmed-meshheading:20849904-Adult,
pubmed-meshheading:20849904-Aged,
pubmed-meshheading:20849904-Cathelicidins,
pubmed-meshheading:20849904-Cells, Cultured,
pubmed-meshheading:20849904-Cytokines,
pubmed-meshheading:20849904-Female,
pubmed-meshheading:20849904-Gene Expression Regulation,
pubmed-meshheading:20849904-Humans,
pubmed-meshheading:20849904-Inflammation,
pubmed-meshheading:20849904-Interleukin-10,
pubmed-meshheading:20849904-Male,
pubmed-meshheading:20849904-Middle Aged,
pubmed-meshheading:20849904-Monocytes,
pubmed-meshheading:20849904-Neutrophils,
pubmed-meshheading:20849904-Psoriasis,
pubmed-meshheading:20849904-T-Lymphocytes,
pubmed-meshheading:20849904-Up-Regulation
|
pubmed:year |
2010
|
pubmed:articleTitle |
Increased serum leucine, leucine-37 levels in psoriasis: positive and negative feedback loops of leucine, leucine-37 and pro- or anti-inflammatory cytokines.
|
pubmed:affiliation |
Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan. nmk@med.teikyo-u.ac.jp
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|